Phytohormone Strigolactams Overcomes Oxaliplatin Resistance in Colorectal Cancer by Blocking the Late-Stage Autophagy to Tip the Metabolic Balance toward Ferroptosis.

Primary and acquired oxaliplatin (OXA)-resistance remains a major challenge in colorectal cancer (CRC) therapy. In this work, the type-II strigolactam SL 39 was identified as a promising lead compound against OXA-resistant HCT116R cells. Co-treatment of SL 39 with OXA restored its sensitivity to HCT116R cells and inhibited xenograft tumor growth. Mechanistically, SL 39-treatment specifically blocked the autophagosome-lysosome fusion in HCT116R cells without altering lysosomal pH, leading to induction of mitochondrial dysfunctions and lethal accumulation of reactive oxygen species. Additionally, SL 39 also markedly increased lipid peroxidation and suppressed the SLC7A11/GPX4 axis to trigger ferroptosis in HCT116R cells. Combining SL 39 with OXA delivered a one-two punch: OXA causes DNA damage and oxidative stress, while SL 39 prevents stress resolution─shifting resistant cells toward ferroptotic death. These findings establish that SL 39 blocks late-stage autophagy to tip the metabolic balance toward ferroptosis in chemoresistant CRC, which offers a novel approach to overcome late-stage treatment failure.

• Publication year

  2025

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2025-11-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1021/acs.jmedchem.5c02567PMID 41208142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of oxaliplatin-based chemotherapy as first-line treatment in elderly patients with metastatic colorectal cancer: a meta-analysis

  2025cited by this paper
• Ferroptosis-related oxaliplatin resistance in multiple cancers: Potential roles and therapeutic Implications

  2024cited by this paper
• The PB1 and the ZZ domain of the autophagy receptor p62/SQSTM1 regulate the interaction of p62/SQSTM1 with the autophagosome protein LC3B

  2023cited by this paper
• Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors

  2023cited by this paper
• Flavonoids from Scutellaria barbata D. Don exert antitumor activity in colorectal cancer through inhibited autophagy and promoted apoptosis via ATF4/sestrin2 pathway.

  2022cited by this paper
• Targeting ferroptosis as a vulnerability in cancer

  2022cited by this paper
• Development of Strigolactones as Novel Autophagy/Mitophagy Inhibitors against Colorectal Cancer Cells by Blocking the Autophagosome-Lysosome Fusion.

  2022cited by this paper
• Autophagy: A Versatile Player in the Progression of Colorectal Cancer and Drug Resistance

  2022cited by this paper
• Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

  2022cited by this paper
• Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

  2021cited by this paper
• PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells

  2021cited by this paper
• Access to benzene-modified 2nd generation strigolactams and GR24 by merging C-H olefination with decarboxylative Giese cyclization.

  2021cited by this paper
• Strigolactones, from Plants to Human Health: Achievements and Challenges

  2021cited by this paper
• Mitochondrial regulation of ferroptosis

  2021cited by this paper
• Molecular Mechanisms of Autophagy Regulation in Plants and Their Applications in Agriculture

  2021cited by this paper
• Targeting autophagy with small molecules for cancer therapy

  2019cited by this paper
• Targeting Autophagy in Cancer: Recent Advances and Future Directions.

  2019cited by this paper
• Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis

  2018cited by this paper
• Tetrazolium salts and formazan products in Cell Biology: Viability assessment, fluorescence imaging, and labeling perspectives.

  2018cited by this paper
• Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors

  2017cited by this paper
• Global patterns and trends in colorectal cancer incidence and mortality

  2016cited by this paper
• Recent insights into the function of autophagy in cancer

  2016cited by this paper
• Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair

  2016cited by this paper
• Autophagy in malignant transformation and cancer progression

  2015cited by this paper
• Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN)

  2015cited by this paper
• Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model

  2015cited by this paper
• Regulation of ferroptotic cancer cell death by GPX4.

  2014cited by this paper
• Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogramed primary prostate cancer cells.

  2014cited by this paper
• Autophagy in human health and disease.

  2013cited by this paper
• Autophagy Protects against Oxaliplatin-Induced Cell Death via ER Stress and ROS in Caco-2 Cells

  2012cited by this paper
• Strigolactones: a novel class of phytohormones that inhibit the growth and survival of breast cancer cells and breast cancer stem-like enriched mammosphere cells

  2012cited by this paper
• Ferroptosis: an iron-dependent form of nonapoptotic cell death.

  2012cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment

  2007cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper

• No citing papers are available for this paper.